Search This Blog

Thursday, July 5, 2018

Valeritas started at buy by Oppco


Valeritas initiated with an Outperform at Oppenheimer. Oppenheimer analyst Steven Lichtman started Valeritas with an Outperform rating and $3.50 price target, citing its unique insulin delivery system, large market opportunity and drivers ahead.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)